Literature DB >> 31342370

Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications.

Whitney A Young1, Amy C Degnim1, Tanya L Hoskin2, James W Jakub1, Minh-Doan Nguyen1, Nho V Tran1, Christin A Harless1, Oscar J Manrique1, Judy C Boughey1, Tina J Hieken3.   

Abstract

BACKGROUND: The enhanced esthetics and demonstrated oncologic safety of nipple-sparing mastectomy (NSM) in selected patients have resulted in increased rates among patients with locally advanced breast cancer and/or additional risk factors (obesity, prior radiation, surgery). Limited data exist on complication and reconstruction success rates in a contemporary patient cohort with expanded indications for NSM.
METHODS: With institutional review board (IRB) approval, patients treated from 2009 to 2017 with NSM were identified from our prospective breast surgery registry. Main outcomes were 30-day complications requiring treatment and 1-year reconstruction failure rates. Risk factors were assessed using logistic regression.
RESULTS: We evaluated 1301 breasts in 769 women undergoing NSM for cancer (n = 555) or risk reduction (n = 746) with median age of 48 (range 21-77) years. The overall 30-day complication rate was 7.5% (97/1301 breasts) and declined from 14.8% in 2009 to 6.3% in 2017 (p < 0.001), while the proportion of patients with obesity (p = 0.007) and treated with neoadjuvant chemotherapy (p < 0.001) increased. Prior radiation [odds ratio (OR) 2.35, p = 0.04], recent/current smoking (OR 3.37, p < 0.001), and body mass index (BMI) (OR 1.28 per 5-kg/m2 increase, p = 0.03) significantly increased 30-day complication rates. Reconstruction success at 1 year was 96.7%. Prior radiation (OR 5.65, p < 0.001), axillary surgery (OR 2.55, p = 0.006), and postoperative adjuvant radiation (OR 3.22, p = 0.007) significantly affected 1-year reconstruction failure.
CONCLUSION: The 30-day complication rates of NSM decreased, despite broadened indications among higher-risk patients over time. These data confirm a team learning curve with NSM and also demonstrate that the nipple-sparing approach is suitable for appropriately selected higher-risk patients for both risk reduction and cancer treatment.

Entities:  

Mesh:

Year:  2019        PMID: 31342370     DOI: 10.1245/s10434-019-07560-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.

Authors:  Benjamin D Smith; Matthew P Goetz; Judy C Boughey
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

2.  Nipple-sparing mastectomy for early breast cancer: the importance of intraoperative evaluation of retroareolar margins and intra-nipple duct removal.

Authors:  Rebeca Neves Heinzen; Alfredo Carlos Simões Dornellas de Barros; Filomena Marino Carvalho; Fernando Nalesso Aguiar; Cristiane da Costa Bandeira Abrahão Nimir; Alfredo Luiz Jacomo
Journal:  Gland Surg       Date:  2020-06

Review 3.  Clinical outcomes of patients after nipple-sparing mastectomy and reconstruction based on the expander/implant technique.

Authors:  Uhi Toh; Miki Takenaka; Nobutaka Iwakuma; Yoshito Akagi
Journal:  Surg Today       Date:  2020-11-13       Impact factor: 2.549

4.  Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy.

Authors:  Tracy-Ann Moo; Carolina Rossi Saccarelli; Elizabeth J Sutton; Varadan Sevilimedu; Kate R Pawloski; Timothy M D'Alfonso; Mary C Hughes; Jill S Gluskin; Almir Bitencourt; Elizabeth A Morris; Audree Tadros; Monica Morrow; Mary L Gemignani; Virgilio Sacchini
Journal:  Ann Surg Oncol       Date:  2021-04-17       Impact factor: 4.339

5.  "Tear-Drop Appearance" Wrap: A Novel Implant Coverage Method for Creating Natural Contour in Prepectoral Prosthetic-Based Breast Reconstruction.

Authors:  Hong-Il Kim; Byeong-Seok Kim; Jin-Hyung Park; Hyung-Suk Yi; Hyo-Young Kim; Jin-Hyuk Choi; Sung-Ui Jung; Yoon-Soo Kim
Journal:  J Clin Med       Date:  2022-08-05       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.